| HOME >> BIOLOGY >> TECHNOLOGY |
-- Third Sequential Profitable Quarter --
-- Conference Call on Monday, March 31, 2008 at 9:00 a.m. ET --
BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:
SVA), a leading provider of vaccines in China, today announced unaudited
financial results for the three months and twelve months ended December 31,
2007.
Highlights
-- Record full year 2007 sales of $33.5 million, up 118% year-over-year
-- Record full year 2007 net income of $7.7 million, or $0.19 per share
-- Fourth quarter 2007 sales increased 49% year-over-year to $9.2 million
-- Fourth quarter 2007 operating income rose 460% year-over-year to
$3.3 million
-- Fourth quarter 2007 net income increased to $2.0 million, or $0.05
per share
-- Reported positive preliminary Phase II results for pandemic influenza
(H5N1) whole viron vaccine
-- Sold 5.12 million doses of Healive(R) in 2007, up from 2.6 million
in 2006
-- Sold 1.59 million doses of Anflu(R) in 2007, up from 77,000 doses in
in 2006
Mr. Weidong Yin, Chairman, President and CEO, stated, ''2007 was a
record year for Sinovac from a commercialization and a clinical development
standpoint. Exceeding our internal projections for year-over-year sales
growth, our 2007 sales increased 118%, due to higher than anticipated sales
of our lead products, Healive(R), our inactivated hepatitis A vaccine, and
Anflu(R), our seasonal influenza vaccine, based on the proactive efforts of
our sales organization across China. In addition, we entered a promotion
agreement with GSK China for our seasonal influenza vaccine, Anflu(R), and
successfully launched a marketing campaign that yielded sales in the second
half of the year. We advanced the clinical development of our pandemic
influenza vaccine formulations. We successfully completed the Phase II
trial of our whole viron vaccine in 2007 that led to
'/>"/>
| SOURCE Sinovac Biotech Co., Ltd. Copyright©2008 PR Newswire. All rights reserved |